Abstract Anthocyanins, plant pigments in fruits and berries, have been shown to delay cancer development in rodent models of carcinogenesis, especially those of the colorectal tract. Anthocyanins and anthocyanidins, their aglycons, especially cyanidin and delphinidin, have been subjected to extensive mechanistic studies. In cells in vitro, both glycosides and aglycons engage an array of anti-oncogenic mechanisms including anti-proliferation, induction of apoptosis and inhibition of activities of oncogenic transcription factors and protein tyrosine kinases. Anthocyanins and anthocyanidins exist as four isomers, interconversion between which depends on pH, temperature and access to light. Anthocyanidins are much more prone to avid chemical decomposition than the glycosides, and they only survive for minutes in the biophase. These pharmaceutical issues are very important determinants of the suitability of these Xavonoids for potential development as cancer chemopreventive drugs, and they have hitherto not received adequate attention. In the light of their robust cancer chemopreventive eYcacy in experimental models and their superior stability as compared to that of the aglycons, the anthocyanins seem much more suitable for further drug development than their anthocyanidin counterparts.
Introduction
Epidemiological studies suggest that consumption of certain diets, for example fruits, vegetables and Wbre, can reduce the risk of developing cancer. Therefore, in recent years, the putative cancer chemopreventive properties of dietary constituents have become a focus of intense scrutiny. The search for eYcacious and safe diet-derived alternatives to pharmaceuticals exempliWed by aspirin, Wnasteride and tamoxifen, has been rendered even more relevant in the light of the realisation that diet constituents, in addition to delaying the onset of certain cancers, may also augment the eYcacy of chemotherapeutic drugs in the treatment of established disease [1] . The plethora of published studies on mechanisms which may mediate chemopreventive or co-chemotherapeutic eVects of dietary constituents contrasts sharply with a dearth of information on their clinical pharmacological and pharmaceutical properties. Whilst such information is vital to help adjudge the suitability of developing them as potential drugs, it tends to attract insuYcient attention by researchers in the Weld. Carried away by the enthusiasm generated by a particularly intriguing biochemical property in cells in vitro of the dietary component under study, they often conclude articles describing the novel mechanism to propose that the intervention in question "…could be developed as agent for the management of cancer…". Such statements are often premature, if not out of place, because pharmacological and pharmaceutical issues including stability, bioavailability and formulatability of the dietary constituent need to be taken into account before it can, even remotely, be considered for further drug development. This argument is particularly germane in the light of the precarious stability and bioavailability of many polyphenolic phytochemicals. The present review illustrates these issues focusing on anthocyanins, water-soluble pigments which occur abundantly in fruits and berries, and anthocyanidins, their aglycons. It summarizes the evidence for their cancer chemopreventive eYcacy and juxtaposes it with their clinical pharmacology and pharmaceutical properties. The objective of the review is to highlight properties of this class of Xavonoids which may deWne generic criteria applicable to the development of dietary agents.
Pharmaceutical properties
The anthocyanins found most commonly in higher plants are the glycosides of the six anthocyanidins, with percentage abundance in brackets, cyanidin (50%), pelargonidin (12%), peonidin (12%), delphinidin (12%), petunidin (7%) and malvidin (7%) (Fig. 1) [2] . The most common sugar components of anthocyanins are glucose, galactose and arabinose, usually conjugated to the C3 hydroxyl group in the anthocyanidin C ring. To date, in excess of 400 naturally occurring anthocyanins have been identiWed [2] .
The pharmaceutical Achilles heel of anthocyanidins and anthocyanins is their existence as several molecular forms in equilibrium with each other which depends highly on temperature, pH and presence of light and oxygen [3] . At pH <2 a relatively stable Xavylium cation predominates, responsible for the intense red colouration (Fig. 2a) . Increasing pH is accompanied by rapid loss of a proton generating a blue quinoidal base. Hydration of the Xavylium cation yields a colourless carbinol pseudo-base. This species tautomerises, through opening of the C ring, to generate a yellow chalcone (Fig. 2a) . Both glycosides and aglycons can spontaneously degrade to a phenolic acid and phloroglucinol aldehyde (Fig. 2b) , the latter probably via the intermediate trihydroxyphenyl acetaldehyde, both rather elusive species. The rate of breakdown diVers dramatically between anthocyanins and their aglycons (vide infra).
The dosage forms in which anthocyanins have been administered in preclinical rodent experiments and clinical trials have been almost exclusively berry preparations, single agents have been administered in only a few studies.
Pharmacokinetics and metabolism
ADME investigations have focussed almost exclusively on anthocyanin-rich plant products, i.e. naturally occurring mixtures of anthocyanins. Anthocyanins are rapidly absorbed and eliminated. Their bioavailability has been found to be consistently low across animal species including humans (reviewed in [3] ). It is important to note two analytical chemical issues which complicate the interpretation of the ADME of anthocyanins and anthocyanidins. Firstly, species not absorbed in the upper gastrointestinal tract can be degraded and/or biotransformed by the gut microXora to furnish small phenolic aldehydes and acids undetectable by the analytical methods usually employed to measure anthocyanins or their aglycons [4] . Secondly, almost all analytical methods which have been used to measure these Xavonoids involve acidiWcation of biomatrix samples to transform species present at neutral pH, i.e. colourless carbinol pseudo-base and chalcone forms, into the Xavylium cation (Fig. 2a) . Metabolic conversion which impedes this conversion would result in failure to detect the analyte [5] . These issues illustrate that the clinical pharmacology of anthocyanins warrants much more study involving Malvidin R 1 = OCH 3 R 2 = OCH 3 R 3 = Glucose, galactose or arabinose novel analytical approaches. Protocatechuic acid, generated from cyanidin-3-glucoside chemically and metabolically in the microXora, has recently been measured in human plasma at concentrations far in excess of the anthocyanin consumed as a constituent of Sicilian blood oranges [6] . However, formation in vivo of protocatechuic acid as a major cyanidin glycoside metabolite seems to be speciesdependent, as it was not found in the biophase of rats on cyanidin-3-glucoside [7] . Glucuronidated and methylated conjugates are major metabolites of anthocyanins, and such species have been isolated from human urine and plasma [8, 9] . Aglycones and sulphate conjugates have been identiWed as minor metabolites in human urine [10] [11] [12] . The presence of aglycones has also been demonstrated in jejunal tissue and plasma of rodents on oral anthocyanins [13] and, indirectly, in pigs which consumed a chokeberry extract. In the latter study, identiWcation of cyanidin monoglucuronide in the urine implied intermediate formation of the aglycon [14] .
Preclinical evidence for cancer chemopreventive properties
Anthocyanins and anthocyanidins, predominantly in the form of mixtures, have demonstrated cancer chemopreventive properties in animal models of breast, skin, oesophageal, lung, oral and gastrointestinal carcinogenesis (Table 1) . Evidence for eYcacy is arguably most convincing for the latter, as illustrated by the following examples: supplementation of the diet with 0.3% mirtocyan, a standardised bilberry extract containing 15 anthocyanins, caused about 30% reduction in tumour number and burden in Apc Min mice, a model of human familial adenomatous polyposis [15] . Isolated cyanidin-3-glucoside at that dose was similarly eYcacious. This study identiWed anthocyanin concentrations in the blood and gastrointestinal tract associated with eYcacy. An anthocyanin-rich extract derived from tart cherries reduced adenoma multiplicity but not size in this model [16] . In another study, Apc Min mice received either a mixture of anthocyanins or pure cyanidin in their drinking water at 800 mg/l or 200 mg/l, respectively. A third group received dietary supplementation with 20% freeze-dried tart cherries [17] . The number and burden of caecal adenomas was reduced in all mice that received Xavonoids compared to those that consumed a control diet, without an eVect on small intestinal or colonic adenomas. Anthocyanins have also exhibited chemopreventive ᭣ properties in chemically-induced models of colorectal carcinogenesis. Rats received 1,2 dimethylhydrazine (DMH) to induce colorectal adenomas and carcinomas followed by dietary supplementation (at 5%) with extracts of purple corn, purple sweet potato or red cabbage and the carcinogen 2-amino-1-methyl-6-phenylimidazopyridine (PhIP) which induces aberrant crypt foci (ACF) [18, 19] .The average number of adenomas and adenocarcinomas was signiWcantly reduced in rats which received Xavonoids compared to controls. Induction of ACF by PhIP was signiWcantly inhibited by purple corn and red cabbage colourings. Dietary supplementation with up to 10% lyophilized black raspberries signiWcantly reduced azoxymethane-induced colorectal adenocarcinoma and ACF multiplicity in rats [20] . Anthocyanin-rich extracts of bilberry, chokeberry and grape also inhibited the development of ACF in this model [21] . Whilst all of these data strongly indicate chemopreventive eYcacy of anthocyanins in rodent models of carcinogenesis, we know hardly anything about diVerences in potency in these models between individual anthocyanin molecules.
Clinical evidence for cancer chemopreventive properties
Anthocyanin-rich fruit or berry preparations have been investigated in healthy volunteers or individuals at high risk of developing cancer. Table 2 lists such studies and endpoints germane to cancer chemoprevention. Freeze-dried black raspberry gel was topically applied four times per day to 17 patients with oral intraepithelial neoplasia [22] . After 6 weeks pre-and posttreatment biopsies were evaluated for change in histopathology grade. Seven patients showed histopathological improvement, six exhibited stable disease and four evidence of progression. A reduction in loss of heterozygosity at tumour suppressor gene-associated loci was also observed. Loss of heterozygosity is linked to the development of many human cancers, including oral squamous cell carcinoma. There was an association, although relatively weak, between reduction in loss of heterozygosity and improvement in histopathology grade [22] . Trials of black raspberry powder are currently ongoing in patients with familial adenomatous polyposis who have undergone a subtotal colectomy with ileorectal anastomosis [23] . Over a period of 9 months, patients take two black raspberry powder suppositories daily in combination with an oral dose of 20 g of black raspberry powder or placebo. Endoscopic biopsies are obtained at baseline, 18 and 36 weeks. Preliminary data from 18 weeks suggests that consumption of this powder may be associated with rectal polyp regression. Twenty patients with Barrett's oesophagus have been recruited into a trial of this berry preparation [23, 24] . They consumed up to 45 g of black raspberry powder daily for 6 months. Endoscopic biopsies were obtained before and after treatment. Limited data to date suggests that the length of Barrett's lesions were unaltered by treatment. When urinary markers of oxidative stress were assessed, 8-epi-prostaglandin F2 was signiWcantly reduced, but there was no signiWcant change in mean urinary levels of 8-oxo-7,8-dihydro-2Ј-deoxyguanosine.
Recently, 25 patients with conWrmed colorectal cancer received mirtocyan daily for 7 days before they underwent colectomy or resection of hepatic metastases [25] . Daily dose levels were equivalent to 0.5, 1.0 or 2.0 g of anthocyanins. Mirtocyan consumption caused a small decrease in proliferation and small increase in apoptosis in tumour tissue. Total levels of anthocyanins achieved in the biophase resembled those accompanying eYcacious doses in the Apc Min mouse [15] when doses were compared on the basis of body surface.
The case for anthocyanidins as potential drugs
Anthocyanidins possess intriguing anticarcinogenic properties. They inhibit the growth of a range of tumour cells and induce apoptosis [26] [27] [28] [29] [30] [31] [32] [33] . Delphinidin and cyanidin have been shown to inhibit the protein tyrosine kinase activity of the epidermal growth factor receptor and downstream events [33] [34] [35] [36] . Anthocyanidins bearing methoxy moieties in the B-ring like malvidin interfered with 3Ј,5Ј-cAMP-speciWc phosphodiesterase PDE4 [34] . Delphinidin induced apoptosis and inhibited NF B signalling in prostate tumour cells in vitro and in a human prostate tumour xenograft in nude mice in vivo [26] . These Wndings have engendered the suggestion that delphinidin might be considered for development as potential anticancer agent. As intriguing as the mechanistic observations are, the suitability of this or other anthocyanidins for drug development needs to be interpreted in the light of their exquisite chemical instability, which confounds their clinical potential. In cell culture medium, delphinidin and cyanidin broke down with halflives of less than 30 min, whilst the half-lives of pelargonidin and peonidin were approximately an hour [32] . Furthermore, anthocyanidins generate hydrogen peroxide in cellular incubations, so that their cell growth-inhibitory eYcacy in vitro may well have been the combined eVect of a complicated mixture of phloroglucinol aldehyde, phenolic acid, hydrogen peroxide and parent compound. The stability of anthocyanidins in plasma and tissues has not been clearly deWned, except that they broke down rapidly in the presence of intestinal microXora [37] . Anthocyanidins released locally from their glycosides have been suspected to mediate, at least in part, the eYcacy of anthocyanins. Consistent Colorectum, DMH-and PhIPtreated rats [18] Purple corn colour 1.1 32 # Aberrant crypt foci (colon) # Adenoma number (colon) # Adenocarcinoma number (colon) M Extra-colonic tumours Colorectum, DMH-and PhIPtreated rats [19] Purple sweet potato colour with this notion, formation of anthocyanidins from anthocyanins has been demonstrated in the biomatrix in vivo (vide supra), however, at miniscule concentrations. Therefore, it is possible, but not likely, that the anthocyanidins mediate the pharmacological eVects of their parent glycosides.
The case for anthocyanins as potential drugs
Just like anthocyanidins, anthocyanins engage anticarcinogenic mechanisms in cells in vitro exempliWed by interference with cell proliferation, induction of apoptosis, cell cycle arrest and antioxidation [38] . Anthocyanins have been shown to aVect targets germane to oncogenesis such as AP-1, MAPK, NF-B, and COX-2, as illustrated by the properties of cyanidin-3-glucoside in A549 human lung tumour cells in vitro and in nude mouse bearing this tumour in vivo [39] . Mirtocyan at a concentration of 10 g/ml inhibited the receptor tyrosine kinases EGFR, ErbB2, ErbB3, VEGFR-2 and VEGFR-3 [40] . So the case for advocating anthocyanins for drug development on mechanistic grounds is similar to that for anthocyanidins. Like their aglycons, anthocyanins are systemically poorly available, mainly due to exquisite susceptibility towards biotransformation. Where they diVer is with Skin, TPA-and DMBA-treated mice [57] Grape seed polyphenols (GSP) (Fig. 2b) . In human plasma cyanidin-and delphinidin-3-glucosides were stable for 4 h at room temperature, and on long-term storage at ¡80°C for 2 months [41] .
Conclusion
Existence as a mixture of isomers and propensity to undergo extensive metabolism are two properties which militate against the suitability of either anthocyanidins or anthocyanins for development as drugs. 
